These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 20367532

  • 1. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J.
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [Abstract] [Full Text] [Related]

  • 2. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
    Saad F, Lipton A.
    Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
    [Abstract] [Full Text] [Related]

  • 3. Src as a therapeutic target in men with prostate cancer and bone metastases.
    Saad F.
    BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
    [Abstract] [Full Text] [Related]

  • 4. Zibotentan for the treatment of castrate-resistant prostate cancer.
    Shepard DR, Dreicer R.
    Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
    [Abstract] [Full Text] [Related]

  • 5. Bone targeted therapies in metastatic castration-resistant prostate cancer.
    Rajpar S, Fizazi K.
    Cancer J; 2013 Jul; 19(1):66-70. PubMed ID: 23337759
    [Abstract] [Full Text] [Related]

  • 6. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
    Mayer EL, Krop IE.
    Clin Cancer Res; 2010 Jul 15; 16(14):3526-32. PubMed ID: 20634194
    [Abstract] [Full Text] [Related]

  • 7. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S, Djelloul S, Raymond E.
    Semin Oncol; 2006 Aug 15; 33(4):407-20. PubMed ID: 16890796
    [Abstract] [Full Text] [Related]

  • 8. Novel targeted therapies for prostate cancer.
    Macfarlane RJ, Chi KN.
    Urol Clin North Am; 2010 Feb 15; 37(1):105-19, Table of Contents. PubMed ID: 20152524
    [Abstract] [Full Text] [Related]

  • 9. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.
    Ojemuyiwa MA, Madan RA, Dahut WL.
    Expert Opin Emerg Drugs; 2014 Dec 15; 19(4):459-70. PubMed ID: 25345821
    [Abstract] [Full Text] [Related]

  • 10. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA, Galle PR.
    Expert Opin Investig Drugs; 2010 May 15; 19(5):615-29. PubMed ID: 20374038
    [Abstract] [Full Text] [Related]

  • 11. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
    Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA.
    Cancer Res; 2007 Feb 15; 67(4):1580-8. PubMed ID: 17308097
    [Abstract] [Full Text] [Related]

  • 12. Emerging MEK inhibitors.
    McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M.
    Expert Opin Emerg Drugs; 2010 Jun 15; 15(2):203-23. PubMed ID: 20151845
    [Abstract] [Full Text] [Related]

  • 13. Anti-endothelin drugs in solid tumors.
    Russo A, Bronte G, Rizzo S, Fanale D, Di Gaudio F, Gebbia N, Bazan V.
    Expert Opin Emerg Drugs; 2010 Mar 15; 15(1):27-40. PubMed ID: 20102289
    [Abstract] [Full Text] [Related]

  • 14. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
    Tenta R, Sotiriou E, Pitulis N, Thyphronitis G, Koutsilieris M.
    J Musculoskelet Neuronal Interact; 2005 Jun 15; 5(2):135-44. PubMed ID: 15951629
    [Abstract] [Full Text] [Related]

  • 15. Tyrosine kinase inhibitors to treat liver cancer.
    Huynh H.
    Expert Opin Emerg Drugs; 2010 Mar 15; 15(1):13-26. PubMed ID: 20128706
    [Abstract] [Full Text] [Related]

  • 16. SRC inhibitors in metastatic bone disease.
    Boyce BF, Xing L, Yao Z, Yamashita T, Shakespeare WC, Wang Y, Metcalf CA, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6291s-6295s. PubMed ID: 17062716
    [Abstract] [Full Text] [Related]

  • 17. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW, Baseman A, Assikis V, Zhau HE.
    J Urol; 2005 Jan 15; 173(1):10-20. PubMed ID: 15592017
    [Abstract] [Full Text] [Related]

  • 18. Current trials using bone-targeting agents in prostate cancer.
    Tu SM, Lin SH.
    Cancer J; 2008 Jan 15; 14(1):35-9. PubMed ID: 18303481
    [Abstract] [Full Text] [Related]

  • 19. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK.
    J Clin Oncol; 2003 May 15; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [Abstract] [Full Text] [Related]

  • 20. Src inhibitors in lung cancer: current status and future directions.
    Rothschild SI, Gautschi O, Haura EB, Johnson FM.
    Clin Lung Cancer; 2010 Jul 01; 11(4):238-42. PubMed ID: 20630825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.